1.1.Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K. DLL3: an emergingtarget in small cell lung cancer. J Hematol Oncol. 2019 Jun 18;12(1):61. doi:10.1186/s13045-019-0745-2. PMID: 31215500; PMCID: PMC6582566.
2.2.Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL,Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M. DLL3 as an Emerging Targetfor the Treatment of Neuroendocrine Neoplasms. Oncologist. 2022 Nov3;27(11):940-951. doi: 10.1093/oncolo/oyac161. PMID: 35983951; PMCID:PMC9632312.
3.3.Rojo F, Corassa M, Mavroudis D, Öz AB, Biesma B, Brcic L, Pauwels P, SailerV, Gosney J, Miljkovic D, Hader C, Wu M, Almarez T, Penault-Llorca F.International real-world study of DLL3 expression in patients with small celllung cancer. Lung Cancer. 2020 Sep;147:237-243. doi:10.1016/j.lungcan.2020.07.026. Epub 2020 Jul 27. PMID: 32745892.